These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 1355402)

  • 1. Genetic markers as prognostic indicators in breast cancer.
    Wolman SR; Pauley RJ; Mohamed AN; Dawson PJ; Visscher DW; Sarkar FH
    Cancer; 1992 Sep; 70(6 Suppl):1765-74. PubMed ID: 1355402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes.
    Pauley RJ; Gimotty PA; Paine TJ; Dawson PJ; Wolman SR
    Breast Cancer Res Treat; 1996; 37(1):65-76. PubMed ID: 8750529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy.
    Watatani M; Nagayama K; Imanishi Y; Kurooka K; Wada T; Inui H; Hirai K; Ozaki M; Yasutomi M
    Breast Cancer Res Treat; 1993 Dec; 28(3):231-9. PubMed ID: 7912561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The significance of c-erbB-2 and int-2 gene alterations and DNA ploidy pattern for aggressiveness of breast cancer].
    Nagayama K; Watatani M; Maeda S; Imanishi Y; Kurooka K; Wada T; Yasutomi M
    Nihon Geka Gakkai Zasshi; 1993 Oct; 94(10):1144-52. PubMed ID: 7901748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH; Bièche I; Hacène K; Lidereau R
    Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A paradigm for oncogene complementation in human breast cancer.
    Roux-Dosseto M; Martin PM
    Res Virol; 1989; 140(6):571-91. PubMed ID: 2694252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors.
    Nagai MA; Marques LA; Torloni H; Brentani MM
    Oncology; 1993; 50(6):412-7. PubMed ID: 7901824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.
    Gasparini G; Gullick WJ; Bevilacqua P; Sainsbury JR; Meli S; Boracchi P; Testolin A; La Malfa G; Pozza F
    J Clin Oncol; 1992 May; 10(5):686-95. PubMed ID: 1349034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplification of fgfr4 gene in human breast and gynecological cancers.
    Jaakkola S; Salmikangas P; Nylund S; Partanen J; Armstrong E; Pyrhönen S; Lehtovirta P; Nevanlinna H
    Int J Cancer; 1993 May; 54(3):378-82. PubMed ID: 8099571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
    Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
    Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.
    Cuny M; Kramar A; Courjal F; Johannsdottir V; Iacopetta B; Fontaine H; Grenier J; Culine S; Theillet C
    Cancer Res; 2000 Feb; 60(4):1077-83. PubMed ID: 10706127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.
    Berns EM; Foekens JA; van Staveren IL; van Putten WL; de Koning HY; Portengen H; Klijn JG
    Gene; 1995 Jun; 159(1):11-8. PubMed ID: 7607564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GST pi gene is frequently coamplified with INT2 and HSTF1 proto-oncogenes in human breast cancers.
    Saint-Ruf C; Malfoy B; Scholl S; Zafrani B; Dutrillaux B
    Oncogene; 1991 Mar; 6(3):403-6. PubMed ID: 1826346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
    Courjal F; Cuny M; Simony-Lafontaine J; Louason G; Speiser P; Zeillinger R; Rodriguez C; Theillet C
    Cancer Res; 1997 Oct; 57(19):4360-7. PubMed ID: 9331099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis.
    Borg A; Zhang QX; Olsson H; Wenngren E
    Genes Chromosomes Cancer; 1992 Nov; 5(4):311-20. PubMed ID: 1283319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of fine-needle aspiration to the demonstration of ERBB2 and MYC expression by in situ hybridization in breast carcinoma.
    Soini Y; Mannermaa A; Winqvist R; Kamel D; Poikonen K; Kiviniemi H; Pääkkö P
    J Histochem Cytochem; 1994 Jun; 42(6):795-803. PubMed ID: 7910618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classical gene amplifications in human breast cancer are not associated with distant solid metastases.
    Driouch K; Champème MH; Beuzelin M; Bièche I; Lidereau R
    Br J Cancer; 1997; 76(6):784-7. PubMed ID: 9310246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of c-erbB-2 amplification and DNA aneuploidy. Analysis in 78 patients with node-negative breast cancer.
    Babiak J; Hugh J; Poppema S
    Cancer; 1992 Aug; 70(4):770-6. PubMed ID: 1353701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of high-risk breast cancer patients from genetic changes of their tumors.
    Watatani M; Inui H; Nagayama K; Imanishi Y; Nishimura K; Hashimoto Y; Yamauchi E; Hojo T; Kotsuma Y; Yamato M; Matsunami N; Yasutomi M
    Surg Today; 2000; 30(6):516-22. PubMed ID: 10883462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.